Center for accelerated development of drug candidates targeting high threat bacterial infections
Date:
03/01/2025
Lead Investigators:
Summary
To perform studies in a C3HeB/FeJ mouse model of Mycobacterium abscessus lung infection that are reduced to practice to evaluate the efficacy of rifamycin analogs and rifamycin-based combination drug regimens.